GW 274150

Drug Profile

GW 274150

Alternative Names: 274150; GSK 274150

Latest Information Update: 01 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiallergics; Antiasthmatics; Small molecules; Sulfides
  • Mechanism of Action Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allergic rhinitis; Asthma; Chronic obstructive pulmonary disease; Migraine; Rheumatoid arthritis

Most Recent Events

  • 31 Dec 2006 Development discontinued for Rheumatoid arthritis during 2006
  • 30 Nov 2004 Phase-II clinical trials in Rheumatoid arthritis in United Kingdom (PO)
  • 28 May 2004 A study has been added to the Advances in the Treatment of Nausea and Migraine pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top